The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Category Archives: News

Cross-Border Biotech Blog Relaunch

Bloom Burton & Co. is happy to announce that we will be picking up the torch of the Cross-Border Biotech Blog. The new, reinvigorated blog will feature commentary, data, analysis, case studies and interviews from well-known international healthcare executives and investors, as well as from members of the Bloom Burton team.

You can read the blog at its new location here. E-mail subscribers can renew their subscription using the link in the sidebar of the blog’s main page.

Monday Deal Review: March 31, 2014

Welcome to your Monday Biotech Deal Review for March 31, 2014!

Hit the break to see our summary of the past weeks’ biotech news.

 

Read more of this post

Monday Deal Review: March 17, 2014

  Welcome to your Monday Biotech Deal Review for March 17, 2014, and happy St. Patrick’s day to the Irish (or Irish-for-a-day) among us!

This past week saw Patheon complete their plan of arrangement with JLL/Delta Patheon Holdings, wherein JLL/Delta acquired all outstanding shares of Patheon for US$9.32 cash a share. The 2 entities have now been amalgamated and will operate under Patheon Inc., with DSM Pharmaceutical Products also now combined with Patheon.

Read more of this post

Monday Deal Review: March 10, 2014

  Welcome to your Monday Biotech Deal Review for March 10, 2014!

Read more of this post

Monday Deal Review: February 24, 2014

  Welcome to your Monday Biotech Deal Review for February 24, 2014!

Read more of this post

Monday Deal Review: February 10, 2014

  Welcome to your Monday Biotech Deal Review for February 10, 2014! The big news this week was Valeant’s proposed acquisition of another skin care innovator, PreCision Dermatology, for $475 million. Hit the break for more details on this as well as the rest of the week’s major biotech news.

Read more of this post

Monday Deal Review: February 3, 2014

  Welcome to your Monday Biotech Deal Review for February 03, 2014!

This week saw Jamieson Labs complete the sale of their business to CCMP Capital Advisors, LLC.

In the commercial space, Sirona has executed licensing agreements with Obagi Medical Products and Wanbang Biopharmaceuticals in respect of  its patented skin lightening technology and its anti-diabetic SGLT2 inhibitor, respectively.   Regarding the Obagi agreement, Sirona will transfer its patented skin lightening technology and know-how to Obagi. Obagi will be responsible for the manufacturing, distribution and global sales of the final commercial products. Regarding the Wanbang license,  Sirona is transfering responsibility for all funding, clinical development, regulatory requirements, manufacturing, sales and marketing of its SGLT2 inhibitor in China for upfront and milestone payments of up to US$9.5M in addition to royalty payments.

For details and news on these deals, as well as the rest of the week’s major biotech news, hit the break.

Read more of this post

Monday Deal Review: January 27, 2014

  Welcome to your Monday Biotech Deal Review for Janary 27, 2014! This week saw Valeant complete thier acquisition of Solta Medical, Inc. for USD$250 million. Solta Medical provides treatment technologies for aesthetic care options at the consumer and physician level.  Valeant has also announced a share repurchase program to make purchases of up to $1.5 billion of its convertible notes, senior notes, common shares and/or other debt or shares that may be issued. In other news, Atrium Innovations has obtained shareholder and debentureholder approval for a plan or arrangement allowing for the acquisition of the company by corporations backed by the Permira funds and the acquisition by the company of all of its outstanding convertible debentures.

For details and news on these deals, as well as the rest of the week’s major biotech news, hit the break.

Read more of this post

Monday Deal Review: January 20, 2014

  Welcome to your Monday Biotech Deal Review for Janary 20, 2014! This week saw Paladin purchase Triton Pharma,  privately-held, Canadian specialty pharmaceutical company focused on acquiring and in-licensing specialty innovative products with expected sales of $4 million in 2014. This occurs as Paladin continues to be an acquisition target for Endo Health.

In the commercial space, Sirona and Cincennatti Children’s hospital have signed an agreement to develop an anti-aging cream and associated intellectual property incorporating the proprietary technologies of each organization. The resulting new anti-aging product will be patented with the goal of licensing the new technology to a global leader in the cosmetic and consumer packaged good marketplaces.

For details and news on these deals, as well as the rest of the week’s major biotech news, hit the break.

Read more of this post

Monday Deal Review: January 13, 2014

  Welcome to your Monday Biotech Deal Review for Janary 13, 2014! This week saw the closing of a number of financing transactions, as well as Sirona’s announcement of a private placement of up to $5.34 million in proceeds.  Aeterna Zentaris also announced pricing of their public offering, indicating that shares will be sold at US$1.20 per share, with proceeds up to US$12.2 million.

For details on these deals, as well as the rest of the week’s major biotech news, hit the break.

Read more of this post

Monday Deal Review: January 6, 2014

  Welcome to your Monday Biotech Deal Review for Janary 6, 2014! Happy New Year! Things in 2013 slowed considerably as we approached the holiday season, however January has gotten off to a good start.

Hit the break to see this week’s major biotech news, and thank you to Jennifer Ng of Norton Rose Fulbright Canada LLP for conbtributing to this week’s post.

Read more of this post

Monday Deal Review: December 16, 2013

  Welcome to your Monday Biotech Deal Review for December 16, 2013! This week saw Cangene announce thier acqusition by Emergent BioSolutions for CDN$236 million. Further, on the commercial side, Theratechnologies, Stellar Biotechnologies and NEOMED all made announcements in the collaboration space.

Hit the break to see this week’s major biotech news.

Read more of this post

Monday Deal Review: December 9, 2013

  Welcome to your Monday Biotech Deal Review for December 9, 2013!

Hit the break to see this week’s major biotech news.

Read more of this post

Monday Deal Review: December 2, 2013

  Welcome to your Monday Biotech Deal Review for December 2, 2013! Hit the break to see this week’s major biotech news.

Read more of this post

Monday Deal Review: November 25, 2013

  Welcome to your Monday Biotech Deal Review for November 25, 2013! This week saw Patheon enter into an agreement which will take the company private, once the necessary shareholder and court approval is obtained. Futher, Cardiome has closed its acquisition of Swiss-based Correvio in a cash and share deal. On the financing side of things, Aeterna Zentaris announced that it is seeking to raise US$13.7 million with its previosly announced public offering.

Hit the break the see the details on these deals, as well as the rest of the week’s major biotech news.

Read more of this post

Monday Deal Review: November 18, 2013

  Welcome to your Monday Biotech Deal Review for November 18, 2013! This week saw significant activity in the biotech space, so follow the link to see the full week’s worth of major biotech stories!

Read more of this post

Monday Deal Review: November 11, 2013

  Welcome to your Monday Biotech Deal Review for November 11, 2013! This week’s big story was the announcement that Paladin Labs has agreed to be acquired by NASDAQ-listed Endo Health Solutions for $1.7 billion. The deal will lead to existing Paladin shareholders recieving shares in a new holding company (holding both Endo and Paladin shares) and newly formed Canadian public company Knight Therepeutics.

There were many more notable deals this past week, so follow the link to see the full week’s worth of major biotech stories!

Read more of this post

Monday Deal Review: November 4, 2013

  Welcome to your Monday Biotech Deal Review for November 4, 2013! A number of financings have closed in the past week, with a few more placement being announced as well.  Prometric is continuing with its public offering, while OPMEDIC is continuing with its amalgamation which will take the company private.

Follow the link to see the full week’s worth of major biotech stories!

Read more of this post

Monday Deal Review: October 28, 2013

  Welcome to your Monday Biotech Deal Review for October 28, 2013! This week saw some activity in both the M&A and financing spaces, notably involving BELLUS Health, Concordia, Arch Biopartners, Novadaq and others.

Hit the break to catch up on the week’s major biotech news!

Read more of this post

Monday Deal Review: October 21, 2013

  Welcome to your Monday Biotech Deal Review for October 21, 2013! After a busy few weeks in September and October, the past week saw a slow in activity across the sector. Nonetheless, hit the break to get a rundown on this week’s major stories!

Read more of this post

Monday Deal Review: October 14, 2013

  Welcome to your Monday Biotech Deal Review for October 14, 2013!

Of particular note this week is the innovative collaboration between Sirona Biochem and Bloom Burton & Co. The venture seeks to develop and commercialize new therapeutics in the areas of inflammation and infectious disease. Such an arrangement purports to take advantage of Sirona’s proprietary fluorination technology platform, and Bloom Burton’s knowledge of the market and expertise in commercialization, delivering to market products targeted towards rare or neglected inflammatory diseases and bacterial resistance. This model shows significant promise, so look to this space to see how the relationship progresses.

Hit the break to get the full scoop on the week’s major stories!

Read more of this post

Share Price Performance in Q3 2013 for the Canadian Healthcare Sector: An upbeat quarter for the larger cap public companies (Part 1)

Wayne Schnarr - seriousIn order to assess share price performance in 2013 among the Canadian public healthcare companies, I have used an initial portfolio of 118 companies. The portfolio has been split into three parts according to the closing share price on December 31, 2012: $1.00 or more (38 companies); $0.10 to $0.99 (53 companies); and less than $0.10 (originally 27 companies).

In this blog, I am going to comment on the Q3 and 9-month performance of the first group of companies with share prices of $1.00 or more to start 2013. Whereas there is usually little share price movement in the slow summer quarter, Q3 2013 was very upbeat and the performance in the first 9 months of 2013 is actually strong.

Read more of this post

Monday Deal Review: October 7, 2013

  Welcome to your Monday Biotech Deal Review for October 7, 2013! A busy week saw significant activity in both the financing and commercial agreement spaces.  Of note is MedMira recieving a $6.1 million equity investment.

Hit the break for the full rundown of the week’s major biotech news! And thanks again to Jennifer Ng of Norton Rose Fulbright for helping out with this week’s post.

Read more of this post

Monday Deal Review: September 30, 2013

  Welcome to your Monday Biotech Deal Review for September 30, 2013! There has been a lot of activity in the M&A and finanicngs space the last week.  Hit the break for the full rundown of the weeks’s major biotech news!

Read more of this post

Monday Deal Review: September 23, 2013

  Welcome to your Monday Biotech Deal Review for September 23, 2013! Now that we are in the full swing of September, the activity in the market has ramped up.

In terms of M&A, Axxess has purchased the assets of Revive Bioscience, including Revive’s product and IP portfolios, for an undisclosed amount. Easton has re-entered the drug market by purchasing rights in a female sexual arousal disorder drug. And MTPC has completed its acquisition of Medicago. Medicago’s shares are no longer listed as a result.

In terms of financing, IMRIS and Xylitol have both enetered into loan agreements. However, a number of other companies are also rasing capital through placements, including MedMira, Miraculins, and Bioniche .

Theres lots more to report, so hit the break to see the past weeks’ major biotech stories.

Once again, a big thank you to Jennifer Ng for her help in getting these stories to you.

Read more of this post

Monday Deal Review: September 16, 2013

 Welcome to your Monday Biotech Deal Review for September 16, 2013! The last week saw significant activity in financing. Of note is Miraculins $1,000,000 private placement, Sirona’s private placement, and Calyx’s proposal of a new private plcaement in response to the over-subscription of its previously announced offering. Finally, Stellar has raised $10 million in the initial closing of its own private placement.

In other news, Medicago is proceeding with its plan of arrangement after havign recieved court approval for the transaction.

See what else is happening in the biotech space by hitting the break!

Read more of this post

Monday Deal Review: September 9, 2013

Welcome to your Monday Biotech Deal Review for September 9, 2013! This week saw Medicago recieve the shareholder approval it needed in order to continue its arrangement with MTPC.  Cash consideration of $1.16 will be given for each share of Medicago.

For more detail on this deal, as well as the rest of the major recent biotech stories, hit the break!

Read more of this post

Monday Deal Review: August 26, 2013

Welcome to your Monday Biotech Deal Review for August 26, 2013! This week’s big story was the closing of Sophiris Bio’s IPO, which raised $65 million in gross proceeds.  Antibe also closed its own IPO, rasing $3 million in aggregate proceeds.  Finally, Stellar, Biologix Hair, Zecotec Photonics and Nightinggale Informatix have either closed or announced their intent to close private placements of their own.

I’d also like to take this oppurtunity to thank Jennifer Ng, an articling student with Norton Rose Fulbright Canada LLP, who will be assisting in bringing you the Monday Deal Review each week from now on. Thanks Jennifer!

Now hit the break to see the whole story on these major deals and for the rest of the past weeks’ stories!

Read more of this post

Monday Deal Review: August 19, 2013

Welcome to your Monday Biotech Deal Review for August 19, 2013! As August comes to a close, activity is beginning to pick up.  Bellus and Valeant have closed their acquisitions of Thallion and Bausch + Lomb, respectively.  On the financing side of things, Sophiris and Covalon are pursuing offerings, with Sophiris looking at rasing $65 million.  Finally, Transition, Vivione and Quest PharmaTech have executed deals for licensing or development.

Hit the break to see the whole story on these major deals and for the rest of the past weeks’ stories!

Read more of this post

Monday Deal Review: July 22, 2013

Welcome to your Monday Biotech Deal Review for July 22, 2013! A busy week saw acquisitions of Medicago by Mitsubishi Tanabe Pharma Corporation and Allon’s acquisition by Paladin Labs.

Hit the break to see the whole story on these major deals and for the rest of the past weeks’ stories!

Read more of this post

Follow

Get every new post delivered to your Inbox.

Join 131 other followers